Jabbour et al evaluated factors affecting the response of patient with Ph+ chronic myeloid leukemia (CML) in chronic phase to nilotinib. The authors are from multiple hospitals in the Europe and North America.
Patient selection: Ph+ CML, resistant to or intolerant of imatinib, treated with nilotinib